Oxford University Hospitals NHS Foundation Trust (OUH) in Oxford, UK, has begun a clinical trial of a messenger ribonucleic acid (mRNA) vaccine to treat patients with head and neck cancer.
The first subject has been treated in Oxfordshire following the start of the trial.
OUH is carrying out the trial across multiple study centres in Oxford, Southampton and Liverpool.
It will enrol patients with HPV-16 positive advanced, metastatic or unresectable cancers.
Led by OUH consultant clinical oncologist Dr Ketan Shah, the second phase study will evaluate whether the vaccine can boost the effectiveness of immunotherapy.
Dr Shah said: “This is the first mRNA cancer vaccine trial open in Oxford.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“We signed up to this study before Covid-19 made mRNA vaccine technology famous! It is an area we all think will expand rapidly.
“New technology needs to be tested thoroughly against what we currently offer, but we all hope that this approach could be transformative to patient care.”
mRNA cancer vaccines are understood to provide the cancer blueprint for the patient’s immune system, facilitating in detecting and killing the cancer cells.
University of Oxford academic clinical lecturer and national cancer vaccine advance senior government advisor Dr Lennard Lee said: “The Oxford Cancer Centre at OUH has been very successful in bringing new opportunities for patients and is leading the charge for mRNA cancer vaccine trials.
“These mRNA cancer vaccines could be the silver lining of recent years, and an amazing tool for those affected by cancer.”
Earlier this year, the University Hospitals Birmingham NHS Foundation Trust (UHB) was chosen as the first UK site to begin the BioNTech mRNA cancer vaccine trial in patients with high-risk stage II and stage III colorectal cancers.
The trial is expected to enrol 10,000 subjects across the UK.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.